VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis

Thrombosis Research

Volumn 126, Issue 2, 2010, Pages

  Pasmant, Eric ^a   De Beauvoir, Charlotte ^a   Plessier, Aurélie ^a   Labreuche, Julien ^b   Bezeaud, Annie ^a,b  

^a BEAUJON HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Budd Chiari syndrome; CYP2C9; Hepatic vein thrombosis; Vitamin K antagonists; VKORC1

Indexed keywords

CYTOCHROME P450 2C9; MULTIPROTEIN COMPLEX; OSTEOCALCIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; ALLELE; ARTICLE; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 77955713680     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.03.015     Document Type: Letter

References (12)

1. A. Plessier, and D.C. Valla Budd-Chiari syndrome Semin Liver Dis 28 2008 259 269
2. B. Condat, F. Pessione, S. Hillaire, M.H. Denninger, M.C. Guillin, and M. Poliquin Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy Gastroenterology 120 2001 490 497
3. S. Rost, A. Fregin, V. Ivaskevicius, E. Conzelmann, K. Hörtnagel, and H.J. Pelz Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature 427 2004 537 541
4. M.J. Rieder, A.P. Reiner, B.F. Gage, D.A. Nickerson, C.S. Eby, and H.L. McLeod Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 2005 2285 2293
5. E.A. Sconce, T.I. Khan, H.A. Wynne, P. Avery, L. Monkhouse, and B.P. King The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 2005 2329 2333
6. L. Bodin, C. Verstuyft, D.A. Tregouet, A. Robert, L. Dubert, and C. Funck-Brentano Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity Blood 106 2005 135 140
7. Y. Wang, W. Zhang, Y. Zhang, Y. Yang, L. Sun, and S. Hu VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection) Circulation 113 2006 1615 1621
8. K. Lacut, C. Larramendy-Gozalo, G. Le Gal, J. Duchemin, B. Mercier, and L. Gourhant Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study J Thromb Haemost 5 2007 2017 2019
9. L.A. Hindorff, S.R. Heckbert, N. Smith, K.D. Marciante, and B.M. Psaty Common VKORC1 variants are not associated with arterial or venous thrombosis J Thromb Haemost 5 2007 2017 2019
10. D.M. Smadja, M.A. Loriot, L.A. Hindorff, L. Mellottee, P. Gaussem, and J. Emmerich No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease Thromb Haemost 99 2008 970 972
11. H.L. Janssen, J.C. Garcia-Pagan, E. Elias, G. Mentha, A. Hadengue, and D.C. Valla Budd-Chiari syndrome: a review by an expert panel J Hepatol 38 2003 364 371
12. T. Yin, and T. Miyata Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives Thromb Res 120 2007 1 10